{"id":15279,"date":"2025-11-10T18:23:34","date_gmt":"2025-11-10T12:53:34","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=15279"},"modified":"2025-11-10T18:45:28","modified_gmt":"2025-11-10T13:15:28","slug":"mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/","title":{"rendered":"Mahamaya Lifesciences IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<p>In November 2025, India\u2019s SME IPO market continues to see strong activity, with specialty and export-oriented businesses coming to the public markets. Mahamaya Lifesciences Limited, an agrochemicals and crop-protection company with growing exports and product registrations, is opening its IPO on November 11, 2025. Below is a structured look at the company, its IPO, and the sector outlook:<\/p>\n<h2><span class=\"ez-toc-section\" id=\"About_Mahamaya_Lifesciences_Ltd\"><\/span><strong>About Mahamaya Lifesciences Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in the manufacturing, registration, and export of crop protection products and bioproducts for crop and soil health management. It started as an importer\/trader of critical pesticide formulations and now manufactures and supplies bulk and branded formulations to Indian agrochemical companies and MNCs.<\/p>\n<p>Key business lines:<\/p>\n<ul>\n<li><strong>Bulk formulation sales<\/strong> \u2013 Acetamiprid, Buprofezin, Emamectin Benzoate, Imidacloprid, Paraquat Dichloride, etc.<\/li>\n<li><strong>Technical sales<\/strong> \u2013 Acetamiprid Technical 99% min, Atrazine Technical 95% min, Imidacloprid Technical 95% min, Emamectin Benzoate Technical 95% min.<\/li>\n<li><strong>Branded products<\/strong> \u2013 MAYAMRIT GR, MAYAMRIT SL, MAYAGIBB, UCHIT EW 370<\/li>\n<li><strong>Export formulations<\/strong> \u2013 To countries like Dominican Republic, Egypt, Ethiopia, Jordan, UAE, Turkey.<\/li>\n<\/ul>\n<p>The company invests in global product registrations and supplies high-quality formulations with regulatory data support. As of the latest period, it serves domestic clients and exports to multiple geographies.<\/p>\n<p><strong>Promoters:<\/strong><\/p>\n<ul>\n<li>Mr. Krishnamurthy Ganesan<\/li>\n<li>Mrs. Lalitha Krishnamurthy<\/li>\n<li>Mr. Prashant Krishnamurthy<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Mahamaya_Lifesciences_IPO_Details\"><\/span><strong>Mahamaya Lifesciences IPO Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Particulars<\/strong><\/td>\n<td><strong>Details<\/strong><\/td>\n<\/tr>\n<tr>\n<td>IPO Date<\/td>\n<td>November 11, 2025 to November 13, 2025<\/td>\n<\/tr>\n<tr>\n<td>Listing Date<\/td>\n<td>[.]<\/td>\n<\/tr>\n<tr>\n<td>Face Value<\/td>\n<td>\u20b910\u00a0per share<\/td>\n<\/tr>\n<tr>\n<td>Issue Price Band<\/td>\n<td>\u20b9108 to \u20b9114 per share<\/td>\n<\/tr>\n<tr>\n<td>Lot Size<\/td>\n<td>1,200 Shares<\/td>\n<\/tr>\n<tr>\n<td>Sale Type<\/td>\n<td>Fresh Capital-cum-Offer for Sale<\/td>\n<\/tr>\n<tr>\n<td>Total Issue Size<\/td>\n<td>61,78,800\u00a0shares<br \/>\n(aggregating up to \u20b970.44\u00a0Cr)<\/td>\n<\/tr>\n<tr>\n<td>Reserved for\u00a0Market Maker<\/td>\n<td>3,09,600\u00a0shares<br \/>\n(aggregating up to \u20b93.53 Cr)<\/td>\n<\/tr>\n<tr>\n<td>Fresh Issue<br \/>\n(Ex Market Maker)<\/td>\n<td>53,29,200\u00a0shares<br \/>\n(aggregating up to \u20b960.75\u00a0Cr)<\/td>\n<\/tr>\n<tr>\n<td>Offer for Sale<\/td>\n<td>5,40,000\u00a0shares of \u20b910<br \/>\n(aggregating up to \u20b96.16\u00a0Cr)<\/td>\n<\/tr>\n<tr>\n<td>Net Offered to Public<\/td>\n<td>58,69,200\u00a0shares<br \/>\n(aggregating up to \u20b966.91\u00a0Cr)<\/td>\n<\/tr>\n<tr>\n<td>Issue Type<\/td>\n<td>Bookbuilding\u00a0IPO<\/td>\n<\/tr>\n<tr>\n<td>Listing At<\/td>\n<td>BSE SME<\/td>\n<\/tr>\n<tr>\n<td>Share Holding Pre Issue<\/td>\n<td>1,77,66,200\u00a0shares<\/td>\n<\/tr>\n<tr>\n<td>Share Holding Post Issue<\/td>\n<td>2,34,05,000\u00a0shares<\/td>\n<\/tr>\n<tr>\n<td>Lead Manager<\/td>\n<td>Oneview Corporate Advisors Pvt. Ltd.<\/td>\n<\/tr>\n<tr>\n<td>Registrar<\/td>\n<td><a href=\"https:\/\/www.torusdigital.com\/stocks\/kfin-technologies-ltd-share-price\">Kfin Technologies Ltd.<\/a><\/td>\n<\/tr>\n<tr>\n<td>Market Maker<\/td>\n<td>Mansi Share &amp; Stock Broking Pvt. Ltd.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/torusdigital.go.link\/hgQeE\" target=\"_blank\" rel=\"noopener\"><br \/>\n<img decoding=\"async\" class=\"responsive-img\" src=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/07\/Desktop-1.jpg\" alt=\"\" \/><br \/>\n<\/a><\/p>\n<style>\n  .responsive-img {<br \/>    display: block;<br \/>    margin-left: auto;<br \/>    margin-right: auto;<br \/>    width: 100%;<br \/>    max-width: 900px;<br \/><\/style>\n<h3><span class=\"ez-toc-section\" id=\"Important_IPO_Timeline\"><\/span><strong>Important IPO Timeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Event<\/strong><\/td>\n<td><strong>Date<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>IPO Open Date<\/td>\n<td>November 11, 2025 (Tue)<\/td>\n<\/tr>\n<tr>\n<td>IPO Close Date<\/td>\n<td>November 13, 2025 (Thu)<\/td>\n<\/tr>\n<tr>\n<td>Allotment Date (Tentative)<\/td>\n<td>November 14, 2025 (Fri)<\/td>\n<\/tr>\n<tr>\n<td>Initiation of Refunds<\/td>\n<td>November 17, 2025 (Mon)<\/td>\n<\/tr>\n<tr>\n<td>Credit of Shares to Demat<\/td>\n<td>November 17, 2025 (Mon)<\/td>\n<\/tr>\n<tr>\n<td>Listing Date (Tentative)<\/td>\n<td>November 18, 2025 (Tue)<\/td>\n<\/tr>\n<tr>\n<td>Cut-off time for UPI mandate confirmation<\/td>\n<td>5 PM on November 13, 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"IPO_Reservation\"><\/span><strong>IPO Reservation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Investor Category<\/strong><\/td>\n<td><strong>Shares Offered<\/strong><\/td>\n<td><strong>% of Issue<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Maker<\/td>\n<td>3,09,600<\/td>\n<td>5.01%<\/td>\n<\/tr>\n<tr>\n<td>QIB<\/td>\n<td>29,28,000<\/td>\n<td>47.39%<\/td>\n<\/tr>\n<tr>\n<td>NII<\/td>\n<td>8,82,000<\/td>\n<td>14.27%<\/td>\n<\/tr>\n<tr>\n<td>Retail<\/td>\n<td>20,59,200<\/td>\n<td>33.33%<\/td>\n<\/tr>\n<tr>\n<td><strong>Total<\/strong><\/td>\n<td><strong>61,78,800<\/strong><\/td>\n<td><strong>100.00%<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Anchor investors:<\/strong> 17,52,000 shares (\u20b919.97 Cr) on Nov 10, 2025<\/p>\n<ul>\n<li>50% lock-in till Dec 14, 2025<\/li>\n<li>Remaining till Feb 12, 2026<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Mahamaya_Lifesciences_IPO_Lot_Size\"><\/span><strong>Mahamaya Lifesciences IPO Lot Size<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Application<\/strong><\/td>\n<td><strong>Lots<\/strong><\/td>\n<td><strong>Shares<\/strong><\/td>\n<td><strong>Amount<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Retail (Min)<\/td>\n<td>2<\/td>\n<td>2,400<\/td>\n<td>\u20b92,73,600<\/td>\n<\/tr>\n<tr>\n<td>Retail (Max)<\/td>\n<td>2<\/td>\n<td>2,400<\/td>\n<td>\u20b92,73,600<\/td>\n<\/tr>\n<tr>\n<td>S-HNI (Min)<\/td>\n<td>3<\/td>\n<td>3,600<\/td>\n<td>\u20b94,10,400<\/td>\n<\/tr>\n<tr>\n<td>S-HNI (Max)<\/td>\n<td>7<\/td>\n<td>8,400<\/td>\n<td>\u20b99,57,600<\/td>\n<\/tr>\n<tr>\n<td>B-HNI (Min)<\/td>\n<td>8<\/td>\n<td>9,600<\/td>\n<td>\u20b910,94,400<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Mahamaya_Lifesciences_Ltd_Financials\"><\/span><strong>Mahamaya Lifesciences Ltd. Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The company has shown sharp growth in FY25 vs FY24 \u2014 revenue up 64% and PAT up 148%, which the reviewer also flagged as \u201cboosted\u201d and worth watching for sustainability.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Key_Company_Financials_%E2%82%B9_in_crore\"><\/span><strong>Key Company Financials (\u20b9 in crore):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Period Ended<\/strong><\/td>\n<td><strong>30 Jun 2025<\/strong><\/td>\n<td><strong>31 Mar 2025<\/strong><\/td>\n<td><strong>31 Mar 2024<\/strong><\/td>\n<td><strong>31 Mar 2023<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Assets<\/td>\n<td>218.87<\/td>\n<td>188.35<\/td>\n<td>112.07<\/td>\n<td>77.88<\/td>\n<\/tr>\n<tr>\n<td>Total Income<\/td>\n<td>84.04<\/td>\n<td>267.17<\/td>\n<td>162.83<\/td>\n<td>137.40<\/td>\n<\/tr>\n<tr>\n<td>Profit After Tax<\/td>\n<td>4.10<\/td>\n<td>12.94<\/td>\n<td>5.22<\/td>\n<td>3.75<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>8.04<\/td>\n<td>24.64<\/td>\n<td>13.36<\/td>\n<td>8.91<\/td>\n<\/tr>\n<tr>\n<td>Net Worth<\/td>\n<td>53.50<\/td>\n<td>49.42<\/td>\n<td>24.66<\/td>\n<td>19.44<\/td>\n<\/tr>\n<tr>\n<td>Reserves &amp; Surplus<\/td>\n<td>35.73<\/td>\n<td>31.66<\/td>\n<td>23.41<\/td>\n<td>18.19<\/td>\n<\/tr>\n<tr>\n<td>Total Borrowing<\/td>\n<td>57.72<\/td>\n<td>58.11<\/td>\n<td>54.63<\/td>\n<td>24.37<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Key_Performance_Indicators_as_of_Mar_31_2025\"><\/span><strong>Key Performance Indicators (as of Mar 31, 2025):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>KPI<\/strong><\/td>\n<td><strong>Value<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>ROE<\/td>\n<td>34.94%<\/td>\n<\/tr>\n<tr>\n<td>ROCE<\/td>\n<td>23.15%<\/td>\n<\/tr>\n<tr>\n<td>Debt \/ Equity<\/td>\n<td>1.08<\/td>\n<\/tr>\n<tr>\n<td>RoNW<\/td>\n<td>26.19%<\/td>\n<\/tr>\n<tr>\n<td>PAT Margin<\/td>\n<td>4.84%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA Margin<\/td>\n<td>9.22%<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>9.40<\/td>\n<\/tr>\n<tr>\n<td>Market Cap (at issue)<\/td>\n<td>\u20b9266.82 Cr<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"EPS_PE_Ratio\"><\/span><strong>EPS &amp; P\/E Ratio<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<tbody>\n<tr>\n<td width=\"50\"><\/td>\n<td width=\"73\">Pre IPO<\/td>\n<td width=\"103\">Post IPO<\/td>\n<\/tr>\n<tr>\n<td width=\"50\"><strong>EPS<\/strong><\/td>\n<td width=\"73\">\u20b97.29<\/td>\n<td width=\"103\">\u20b97.01<\/td>\n<\/tr>\n<tr>\n<td width=\"50\"><strong>P\/E<\/strong><\/td>\n<td width=\"73\">15.65x<\/td>\n<td width=\"103\">16.25x<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Promoter_Holding\"><\/span><strong>Promoter Holding:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><\/td>\n<td><strong>Pre-Issue<\/strong><\/td>\n<td><strong>Post-Issue<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoter Holding<\/td>\n<td>77.27%<\/td>\n<td>56.35%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Objects_of_the_Issue\"><\/span><strong>Objects of the Issue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>S.No.<\/strong><\/td>\n<td><strong>Objects of the Issue<\/strong><\/td>\n<td><strong>Amount (\u20b9 Cr)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Purchase of equipment for existing formulation plant<\/td>\n<td>3.75<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Capex for setting up new technical manufacturing plant<\/td>\n<td>29.42<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Construction of warehouse building &amp; purchase of machinery<\/td>\n<td>2.53<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Funding working capital requirements<\/td>\n<td>18.00<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>General corporate purposes<\/td>\n<td>Balance<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Mahamaya_Lifesciences_Ltd_Industry_Outlook\"><\/span><strong>Mahamaya Lifesciences Ltd.: Industry Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>India is a large, fast-growing agrochemical market, supported by rising crop intensity, export opportunities, and replacement of older molecules.<\/li>\n<li>Companies that import, register, and then formulate newer molecules for Indian conditions can scale faster, especially if they also export to Asia\/Africa\/Middle East, as Mahamaya does.<\/li>\n<li>Global registration-led models create entry barriers but also need continuous capex and working capital.<\/li>\n<li>Government focus on better farm yields and pest management supports demand for specialized formulations.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Mahamaya_Lifesciences_IPO_Peer_Comparison\"><\/span><strong>Mahamaya Lifesciences IPO: Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/www.torusdigital.com\/ipo\/mahamaya-lifesciences-ltd-ipo\">Mahamaya Lifesciences IPO<\/a> can be compared with other players in the <a href=\"https:\/\/www.torusdigital.com\/stocks\/sectors\/agro-chemicals\">agrochemical sector<\/a> such as <a href=\"https:\/\/www.torusdigital.com\/stocks\/dharmaj-crop-guard-ltd-share-price\">Dharmaj Crop Guard Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/insecticides-india-ltd-share-price\">Insecticides India Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/heranba-industries-ltd-share-price\">Heranba Industries Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/p-i-industries-ltd-share-price\">PI Industries Ltd<\/a>, and <a href=\"https:\/\/www.torusdigital.com\/stocks\/sharda-cropchem-ltd-share-price\">Sharda Cropchem Ltd<\/a>. Analyzing these peers provides investors with a broader understanding of Mahamaya Lifesciences\u2019 market positioning, scale of operations, and growth potential within India\u2019s fast-evolving agrochemical industry.<\/p>\n<p><strong>People Also Read:<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/emmvee-photovoltaic-ipo-opens-key-details-investors-shouldnt-miss\/\">Emmvee Photovoltaic IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/physicswallah-ipo-opens-key-details-investors-shouldnt-miss\/\">PhysicsWallah IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/pine-labs-ipo-opens-key-details-investors-shouldnt-miss\/\">Pine Labs IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/shining-tools-ipo-opens-key-details-investors-shouldnt-miss\/\">Shining Tools IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/curis-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/\">Curis Lifesciences IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mahamaya Lifesciences Ltd. offers a play on agrochemicals + exports + product registrations. The company has:<\/p>\n<ul>\n<li>visible growth in FY25 numbers,<\/li>\n<li>a clear plan to add a technical plant,<\/li>\n<li>and well-defined use of IPO proceeds.<\/li>\n<\/ul>\n<p>However, two things a cautious investor may note:<\/p>\n<ol>\n<li><strong>The FY25 jump in revenue and PAT is sharp<\/strong> \u2014 sustainability needs to be watched.<\/li>\n<li><strong>Valuation looks fully\/closely priced<\/strong> for an SME issue, and the minimum application amount is high.<\/li>\n<\/ol>\n<p>For investors comfortable with SME liquidity and the agri-inputs story, it can be looked at with a medium-to-long-term view.<\/p>\n<p>If you are exploring more investment opportunities, check out our dedicated page on\u202f<a href=\"https:\/\/www.torusdigital.com\/ipo\/upcoming-ipo\">upcoming IPO listings<\/a>\u202fto stay updated on the latest market offerings.<\/p>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;share_rating&#8221;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Rate this article<\/h6>\n<!-- FeedbackWP Plugin --><div  class=\"rmp-widgets-container rmp-wp-plugin rmp-main-container js-rmp-widgets-container js-rmp-widgets-container--15279 \"  data-post-id=\"15279\">    <!-- Rating widget -->  <div class=\"rmp-rating-widget js-rmp-rating-widget\">            <div class=\"rmp-rating-widget__icons\">      <ul class=\"rmp-rating-widget__icons-list js-rmp-rating-icons-list\">                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Terrible!\" data-value=\"1\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Bad!\" data-value=\"2\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Okay!\" data-value=\"3\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Good!\" data-value=\"4\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--half-highlight js-rmp-remove-half-star\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Great!\" data-value=\"5\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>              <\/ul>    <\/div>    <p class=\"rmp-rating-widget__hover-text js-rmp-hover-text\"><\/p>    <button class=\"rmp-rating-widget__submit-btn rmp-btn js-submit-rating-btn\">      Submit Rating    <\/button>    <p class=\"rmp-rating-widget__results js-rmp-results \">       <span class=\"rmp-rating-widget__results__rating js-rmp-avg-rating\">3.3<\/span> \/ 5.  <span class=\"rmp-rating-widget__results__votes js-rmp-vote-count\">4<\/span>    <\/p>    <p class=\"rmp-rating-widget__not-rated js-rmp-not-rated rmp-rating-widget__not-rated--hidden\">          <\/p>    <p class=\"rmp-rating-widget__msg js-rmp-msg\"><\/p>  <\/div>  <!--Structured data -->        <\/div>\n<div id=\"emoji-overlay\" style=\"display: none;\">\n<div id=\"overlay-emoji\"><\/div>\n<div id=\"overlay-description\" class=\"emoji-text\"><\/div>\n<\/div>\n<div id=\"rating-popup\">\n<p><span id=\"popup-close\">\u00d7<\/span><\/p>\n<div class=\"popup_message\">\n<div id=\"popup-emoji\"><\/div>\n<div class=\"popup_innermsg\">\n<h5>Thank You for Rating Our Article!<\/h5>\n<p>Your feedback is incredibly valuable to us, and we&#8217;re thrilled to hear your thoughts.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Share this article<\/h6>\n<div class=\"cscra-social square cscra-socials-679c8a1122c00\">\n        <a href=\"\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fmahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss%2F&t=Mahamaya+Lifesciences+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"facebook\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Facebook\" target=\"_blank\"><i class=\"fa fa-facebook\"><\/i><\/a>\n        <a href=\"\/\/twitter.com\/intent\/tweet?text=Mahamaya+Lifesciences+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fmahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"twitter\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Twitter\" target=\"_blank\"><i class=\"fa-brands fa-x-twitter\"><\/i><\/a>\n        <a href=\"https:\/\/api.whatsapp.com\/send?text=Mahamaya+Lifesciences+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss - https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fmahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"whatsapp\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On WhatsApp\" target=\"_blank\"><i class=\"fa fa-whatsapp\"><\/i><\/a>\n        <a href=\"\/\/www.linkedin.com\/shareArticle?mini=true&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fmahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss%2F&title=Mahamaya+Lifesciences+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"linkedin\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Linkedin\" target=\"_blank\"><i class=\"fa fa-linkedin\"><\/i><\/a>\n    <\/div>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;] In November 2025, India\u2019s SME IPO market continues to see strong activity, with specialty and export-oriented businesses coming to the public markets. Mahamaya Lifesciences Limited, an agrochemicals and crop-protection company with growing exports and product registrations, is opening its IPO on November 11, 2025. Below is a structured look at","protected":false},"author":1,"featured_media":14024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[5,169],"tags":[],"class_list":["post-15279","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mahamaya Lifesciences IPO Opens: What Investors Need To Know<\/title>\n<meta name=\"description\" content=\"Mahamaya Lifesciences IPO is a \u20b970.44 crore book-built issue combining fresh issue and OFS. Here are the IPO dates, price band, lot size, financials, and issue objectives in one place.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mahamaya Lifesciences IPO Opens: What Investors Need To Know\" \/>\n<meta property=\"og:description\" content=\"Mahamaya Lifesciences IPO is a \u20b970.44 crore book-built issue combining fresh issue and OFS. Here are the IPO dates, price band, lot size, financials, and issue objectives in one place.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-10T12:53:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-10T13:15:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1441\" \/>\n\t<meta property=\"og:image:height\" content=\"466\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"torus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"torus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mahamaya Lifesciences IPO Opens: What Investors Need To Know","description":"Mahamaya Lifesciences IPO is a \u20b970.44 crore book-built issue combining fresh issue and OFS. Here are the IPO dates, price band, lot size, financials, and issue objectives in one place.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/","og_locale":"en_US","og_type":"article","og_title":"Mahamaya Lifesciences IPO Opens: What Investors Need To Know","og_description":"Mahamaya Lifesciences IPO is a \u20b970.44 crore book-built issue combining fresh issue and OFS. Here are the IPO dates, price band, lot size, financials, and issue objectives in one place.","og_url":"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/","og_site_name":"Blog","article_published_time":"2025-11-10T12:53:34+00:00","article_modified_time":"2025-11-10T13:15:28+00:00","og_image":[{"width":1441,"height":466,"url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","type":"image\/webp"}],"author":"torus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"torus","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/","url":"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/","name":"Mahamaya Lifesciences IPO Opens: What Investors Need To Know","isPartOf":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"image":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"thumbnailUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","datePublished":"2025-11-10T12:53:34+00:00","dateModified":"2025-11-10T13:15:28+00:00","author":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5"},"description":"Mahamaya Lifesciences IPO is a \u20b970.44 crore book-built issue combining fresh issue and OFS. Here are the IPO dates, price band, lot size, financials, and issue objectives in one place.","breadcrumb":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage","url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","contentUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Essex-Marine-Ltd-IPO-1.webp","width":1441,"height":466},{"@type":"BreadcrumbList","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/mahamaya-lifesciences-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Toruscope","item":"https:\/\/www.torusdigital.com\/toruscope\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.torusdigital.com\/toruscope\/.\/news\/"},{"@type":"ListItem","position":3,"name":"Mahamaya Lifesciences IPO Opens: Key Details Investors Shouldn\u2019t Miss"}]},{"@type":"WebSite","@id":"https:\/\/www.torusdigital.com\/toruscope\/#website","url":"https:\/\/www.torusdigital.com\/toruscope\/","name":"Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.torusdigital.com\/toruscope\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5","name":"torus","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"torus"},"sameAs":["https:\/\/stage.torusdigital.com\/blogs"],"url":"https:\/\/www.torusdigital.com\/toruscope\/author\/torus\/"}]}},"_links":{"self":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/comments?post=15279"}],"version-history":[{"count":3,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15279\/revisions"}],"predecessor-version":[{"id":15282,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15279\/revisions\/15282"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media\/14024"}],"wp:attachment":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media?parent=15279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/categories?post=15279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/tags?post=15279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}